About

Prolocor develops a novel test based on FcyRIIa, a protein expressed on the surface of platelets, the blood cells that are involved in thrombosis or clot formation4-5. Most importantly, the expression of FcyRIIa is significantly increased in certain patients with atherosclerotic cardiovascular disease. In those patients, we see a significantly increased risk of subsequent CV events, compared to patients without a corresponding increase in FcyRIIa levels. This dichotomy has enabled us to leverage FcyRIIa as a predictive biomarker for cardiovascular risk.